The effect of exenatide and erythromycin on postprandial symptoms and their relation to gastric functions

What Was Tested

This randomized controlled trial paper looks at Exenatide.

The aim of the study was to investigate this relationship in response to mediators that affect gastric function.

Why It Was Studied

The relationship between abnormal gastric motor function and postprandial abdominal symptoms has not been fully clarified.

Who Took Part

PubMed indexes the participants as young adults and adults, both men and women.

Ten healthy volunteers participated in a 3-way cross-over study of treatment with placebo, exenatide and erythromycin.

Each subject underwent 3-dimensional single photon emission computed tomography to measure fasting and postprandial gastric volumes.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Exenatide.

The comparison arm used a placebo, so changes seen with Exenatide could be set against what happens without it.

Each person switched between Exenatide and the comparison at some point, usually with a gap in between.

The studies were performed at 1-week intervals.

A combined nutrient drink test and cutaneous electrogastrography (EGG) were performed on the next day.

What Was Measured

PubMed files the paper under topics including Electromyography, Erythromycin, Exenatide, Gastric Emptying, Gastrointestinal Agents, Hypoglycemic Agents and Peptides.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2012 (Digestion), a journal based in Switzerland.

More context: the Exenatide compound page, all human trials.